Relevant bibliographies by topics / Diagnosis and monitoring of bladder cancer / Journal articles
To see the other types of publications on this topic, follow the link: Diagnosis and monitoring of bladder cancer.

Journal articles on the topic 'Diagnosis and monitoring of bladder cancer'

Author: Grafiati
Published: 29 March 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Diagnosis and monitoring of bladder cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kawano, Takahito, Yoko Tachibana, Junichi Inokuchi, Jeong-Hun Kang, Masaharu Murata та Masatoshi Eto. "Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer". International Journal of Molecular Sciences 22, № 17 (2021): 9276. http://dx.doi.org/10.3390/ijms22179276.

Full text
Abstract:
Bladder cancer has a high recurrence rate; therefore, frequent and effective monitoring is essential for disease management. Cystoscopy is considered the gold standard for the diagnosis and continuous monitoring of bladder cancer. However, cystoscopy is invasive and relatively expensive. Thus, there is a need for non-invasive, relatively inexpensive urinary biomarker-based diagnoses of bladder cancer. This study aimed to investigate the presence of activated protein kinase Cα (PKCα) in urine samples and the possibility of PKCα as a urinary biomarker for bladder cancer diagnosis. Activated PKCα
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Ling, YaRong Wang, Le Zhao, et al. "Hsp74, a Potential Bladder Cancer Marker, Has Direct Interaction with Keratin 1." Journal of Immunology Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/492849.

Full text
Abstract:
Early diagnosis and prognosis monitoring are very important for the survival of patients with bladder cancer. To identify candidate biomarkers of bladder cancer, we used a combination of techniques including 2-DE, co-IP, western blot, LC-MS/MS, and immunohistochemistry. Hsp74 was identified with high expression in bladder cancer. The cellular location of expression products of gene Hsp74 showed that they were distributed into cytoplasm and keratin 1 was found to be associated with Hsp74. The results provide a new idea to understand the molecular basis of bladder cancer progression and pinpoint
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Chong, Zhao Yang, Xu Zhang, et al. "Hopes and Challenges: Translational Medical Research in Bladder Cancer." Cancer Plus 1, no. 1 (2019): 1. http://dx.doi.org/10.18063/cp.v1i1.189.

Full text
Abstract:
Bladder cancer is a complex disease and could be classified into non-muscle-invasive or muscle-invasive subtypes according to the distinct genetic background and clinical prognosis. It is necessary to find a non-invasive, economical and efficient method for the diagnosis and treatment of bladder cancer. Translational medicine provides such an opportunity. Genomics, proteomics, molecular biology, bioinformatics and the like that aid in studying and exploring the mechanism of bladder cancer development, bladder cancer-related genes, signalling pathways, key molecules or targets can be clearly us
APA, Harvard, Vancouver, ISO, and other styles
4

Wei, Hairong, Weiming Wan, Hui Zhan, Jiansong Wang, and Jian Chen. "The Role of FGFR3 in the Diagnosis and Treatment of Bladder Cancer: A Review." Cancer Plus 3, no. 1 (2021): 28. http://dx.doi.org/10.18063/cp.v3i1.302.

Full text
Abstract:
Bladder cancer is the most common malignant tumor of the urinary system. The muscle-invasive bladder cancer (MIBC) is associated with poor prognosis; therefore, new systemic treatment is urgently needed. Although the prognosis of non-muscle-invasive bladder cancer (NMIBC) is relatively good, it is highly recurrent and requires lifelong monitoring that brings huge burden to patients and medical services. Thus, improving the diagnosis and treatment of bladder cancer is still a very important milestone to achieve. Fibroblast growth factor receptor 3 (FGFR3) gene mutations frequently occur in blad
APA, Harvard, Vancouver, ISO, and other styles
5

Batista, Rui, Nuno Vinagre, Sara Meireles, et al. "Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review." Diagnostics 10, no. 1 (2020): 39. http://dx.doi.org/10.3390/diagnostics10010039.

Full text
Abstract:
Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by invasive tests, namely periodic cystoscopies; this procedure, although a reliable method, is highly uncomfortable for the patient and it is not exempt of comorbidities. Currently, there is
APA, Harvard, Vancouver, ISO, and other styles
6

Schwab, Andrew J., Matthew W. Mitchell, Edward D. Karoly, and Rangaprasad Sarangarajan. "Abstract 5546: Urine metabolomic biomarkers discovery for bladder cancer diagnostics." Cancer Research 83, no. 7_Supplement (2023): 5546. http://dx.doi.org/10.1158/1538-7445.am2023-5546.

Full text
Abstract:
Abstract Current estimates in the United States for 2022 are about 81,180 new cases of bladder cancer diagnosis with about 17,100 deaths from the disease (American Cancer Society). Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer, approximately 70% of newly diagnosed TCC patients have non-muscle invasive bladder cancer (NMIBC) tumors. The gold standards for initial diagnosis and recurrence of TCC, cystoscopy and cytology, are both limited by their inability to visualize certain areas within the bladder or detect low grade tumors.
APA, Harvard, Vancouver, ISO, and other styles
7

Chin, Fee-Wai, Soon-Choy Chan, and Abhi Veerakumarasivam. "Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer." Diagnostics 13, no. 16 (2023): 2641. http://dx.doi.org/10.3390/diagnostics13162641.

Full text
Abstract:
Homeobox genes serve as master regulatory transcription factors that regulate gene expression during embryogenesis. A homeobox gene may have either tumor-promoting or tumor-suppressive properties depending on the specific organ or cell lineage where it is expressed. The dysregulation of homeobox genes has been reported in various human cancers, including bladder cancer. The dysregulated expression of homeobox genes has been associated with bladder cancer clinical outcomes. Although bladder cancer has high risk of tumor recurrence and progression, it is highly challenging for clinicians to accu
APA, Harvard, Vancouver, ISO, and other styles
8

Yang, Zhao, Nan Zhang, Zongyi Shen, et al. "Markers for Early Diagnosis and Post-operative Recurrence Monitoring of Bladder Cancer." Cancer Plus 2, no. 1 (2020): 1. http://dx.doi.org/10.18063/cp.v2i1.270.

Full text
Abstract:
The diagnosis and management of bladder cancer (BC) are high complex due to cancer heterogeneity among patients. Thus, biomarkers play pivotal roles in the diagnosis, prognosis determination, and planning of therapeutic intervention of BC. With years of research and discovery, many candidate markers for BC have emerged. The alterations of nucleosides, proteins, post-translational modifications, and cells are the candidate markers for early diagnosis and post-operative recurrence monitoring of BC. This review mainly discusses the recent progresses in the proteins and nucleosides markers for dia
APA, Harvard, Vancouver, ISO, and other styles
9

Cheng, Timothy H. T., Peiyong Jiang, Jeremy Y. C. Teoh, et al. "Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling." Clinical Chemistry 65, no. 7 (2019): 927–36. http://dx.doi.org/10.1373/clinchem.2018.301341.

Full text
Abstract:
Abstract BACKGROUND The current diagnosis and monitoring of bladder cancer are heavily reliant on cystoscopy, an invasive and costly procedure. Previous efforts in urine-based detection of bladder cancer focused on targeted approaches that are predicated on the tumor expressing specific aberrations. We aimed to noninvasively detect bladder cancer by the genome-wide assessment of methylomic and copy number aberrations (CNAs). We also investigated the size of tumor cell-free (cf)DNA fragments. METHODS Shallow-depth paired-end genome-wide bisulfite sequencing of urinary cfDNA was done for 46 blad
APA, Harvard, Vancouver, ISO, and other styles
10

Kałużewski, Tadeusz, Grzegorz K. Przybylski, Michał Bednarek, et al. "The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable, RB1 and ERBB2 Somatic Mutations." Journal of Personalized Medicine 11, no. 5 (2021): 362. http://dx.doi.org/10.3390/jpm11050362.

Full text
Abstract:
Bladder cancer is one of the most common cancers in global statistics. One of the issues associated with this disease is the high incidence of cases with delayed diagnosis and what factors correlate with worse treatment outcomes. A possible reason for this may be the rather limited availability of non-invasive diagnostic tools. This short communication presents a case of a 68 year old male patient after an ineffective therapy, carried on for several years with symptoms commonly associated with prostate overgrowth that masked a carcinoma in situ of the urinary bladder. Implementation of several
APA, Harvard, Vancouver, ISO, and other styles
11

Treadwell, Jonathan, and Amy Tsou. "PP75 Genetic Testing For Bladder And Kidney Cancer: An Interactive Evidence Map." International Journal of Technology Assessment in Health Care 34, S1 (2018): 96. http://dx.doi.org/10.1017/s0266462318002301.

Full text
Abstract:
Introduction:Recently, voluminous research and commentary have touted genetic and molecular testing to improve the management of urologic cancer. The purposes of such testing include screening, risk assessment, diagnosis, prognosis, pharmacogenetics, and monitoring (for example, recurrence, predicting treatment response). An interactive graphical tool (“evidence map”) would help policy makers examine the current state of research, identify prevailing trends, and prioritize research efforts.Methods:A professional information specialist searched MEDLINE/EMBASE for articles published in 2010 or l
APA, Harvard, Vancouver, ISO, and other styles
12

Zhang, Pu, Yanning Zhang, Wenhao Liu, et al. "A Molecular Beacon Based Surface-Enhanced Raman Scattering Nanotag for Noninvasive Diagnosis of Bladder Cancer." Journal of Biomedical Nanotechnology 15, no. 7 (2019): 1589–97. http://dx.doi.org/10.1166/jbn.2019.2780.

Full text
Abstract:
Current techniques responsible for bladder cancer diagnosis and monitoring are insensitive and invasive. Here, we report a surface-enhanced Raman scattering nanotag for the sensitive diagnosis of bladder cancer using urine samples as a noninvasive approach. The sea-urchin-like Au nanoclusters used in this work exhibit excellent surface-enhanced Raman scattering ability with an enhancement factor of 3.44 × 107. Molecular beacons labeled with Cy3 are covalently anchored to the surface of Au nanoclusters, which serve as a specific recognition site for survivin mRNA. Further a polyethylene glycol
APA, Harvard, Vancouver, ISO, and other styles
13

Godlewski, Dominik, Sara Czech, Dorota Bartusik-Aebisher, and David Aebisher. "Bladder Cancer Basic Study and Current Clinical Trials." Uro 4, no. 3 (2024): 145–96. http://dx.doi.org/10.3390/uro4030012.

Full text
Abstract:
Bladder cancer (BCa) is the fourth most common cancer in men and one of the most common urinary tract cancers, especially in developed countries. The aim of this paper is to comprehensively analyze the biology of bladder cancer, including its epidemiology, etiology, histological types, risk factors, clinical symptoms, and diagnostic methods. The paper presents the dominant histological types of bladder cancer, such as transitional cell carcinoma (TCC), which accounts for 90–95% of cases, squamous cell carcinoma (SCC), and adenocarcinoma, which is much rarer. Risk factors, such as smoking, occu
APA, Harvard, Vancouver, ISO, and other styles
14

Seok, Jaekwon, Yeonjoo Kwak, Sewhan Kim, Eun-Mee Kim, and Aram Kim. "Advances in Liquid Biopsy for Diagnosis of Bladder Cancer." International Neurourology Journal 28, no. 2 (2024): 83–95. http://dx.doi.org/10.5213/inj.2448198.099.

Full text
Abstract:
Bladder cancer (BCa) is the most common malignancy of the urinary system. It has a high recurrence rate and requires longterm follow-up. Significant advances in BCa research have been made in recent years; however, the initial diagnosis and follow-up of BCa relies on cystoscopy, which is an invasive and expensive procedure. Over the past decade, liquid biopsies (e.g., blood and urine) have proven to be highly efficient methods for the discovery of BCa biomarkers. This noninvasive sampling method is used to analyze unique tumor components released into body fluids and enables serial sampling an
APA, Harvard, Vancouver, ISO, and other styles
15

Seo, Soyeon, Sungeun Cho, Kisook Hong, Bongsuk Shim, and Sungwon Kwon. "Usefulness of NMP22 BladderChek for the Diagnosis and Monitoring of Bladder Cancer." Annals of Laboratory Medicine 27, no. 1 (2007): 22–27. http://dx.doi.org/10.3343/kjlm.2007.27.1.22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Fragkoulis, C., K. Stasinopoulos, A. Pappas, et al. "Multiple reaction monitoring study for bladder cancer diagnosis using novel urine biomarkers." European Urology Supplements 15, no. 13 (2016): e1689. http://dx.doi.org/10.1016/s1569-9056(16)30467-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Lintula, Susanna, and Kristina Hotakainen. "Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer." Expert Opinion on Biological Therapy 10, no. 8 (2010): 1169–80. http://dx.doi.org/10.1517/14712598.2010.489546.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Rentsch, Cyrill A., David Christian Müller, Christian Ruiz, and Lukas Bubendorf. "Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer." European Urology 70, no. 1 (2016): 83–84. http://dx.doi.org/10.1016/j.eururo.2016.02.050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Dai, Chao, Tiantian Zheng, Wei Mo, et al. "Clinical applications of urine- and blood-based genome wide copy number study from 1,000 patients with bladder and prostate cancer." Journal of Clinical Oncology 41, no. 6_suppl (2023): 459. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.459.

Full text
Abstract:
459 Background: Liquid biopsy has become increasingly important in cancer diagnosis and disease progression monitoring. Copy number variation is an important characteristic for genitourinary cancer and many other cancer types, where bladder cancer was shown to have the largest copy number alternation among 33 human cancer types from TCGA. We developed PredicineCNB, a companion LP-WGS assay to robustly estimate genome-wide copy number burden (CNB) from plasma and urine clinical samples, which can provide longitudinal disease monitoring in a cost-effective way. Methods: By integrating both fragm
APA, Harvard, Vancouver, ISO, and other styles
20

Eun, Sung-Jong, Jayoung Kim, and Khae Hawn Kim. "Applications of artificial intelligence in urological setting: a hopeful path to improved care." Journal of Exercise Rehabilitation 17, no. 5 (2021): 308–12. http://dx.doi.org/10.12965/jer.2142596.298.

Full text
Abstract:
Artificial intelligence (AI) has been introduced in urology research and practice. Application of AI leads to better accuracy of disease diagnosis and predictive model for monitoring of responses to medical treatments. This mini-review article aims to summarize current applications and development of AI in urology setting, in particular for diagnosis and treatment of urological diseases. This review will introduce that machine learning algorithm-based models will enhance the prediction accuracy for various bladder diseases including interstitial cystitis, bladder cancer, and reproductive urolo
APA, Harvard, Vancouver, ISO, and other styles
21

Setianingsih, Yennie A., Wahjoe Djatisoesanto, Tetuka B. Laksita, and Aryati Aryati. "Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder cancer." Narra J 4, no. 3 (2024): e1142. http://dx.doi.org/10.52225/narra.v4i3.1142.

Full text
Abstract:
Bladder cancer is known for its high recurrence rate and requires constant patient monitoring. To confirm the diagnosis, a tissue sample from a cystoscopy is required, which the patient often avoids. Urine has the potential to be utilized as a diagnostic fluid because of its non-invasive nature and various biomarker contents. The aim of this study was to determine the diagnostic value of cytokeratin fragment-19 (CYFRA21-1) level in urine for diagnosing bladder cancer. This single-center cross-sectional study was performed with eligible inclusion were adults aged ≥18 years who presented with he
APA, Harvard, Vancouver, ISO, and other styles
22

Sampogna, G., S. Musco, L. Gemma, et al. "Monitoring neurogenic bladder for the early diagnosis of bladder cancer: the experience in two tertiary referral centers." European Urology Open Science 32 (October 2021): S57. http://dx.doi.org/10.1016/s2666-1683(21)00808-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Jain, Rohit K., Petros Grivas, and Sumanta K. Pal. "Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?" BJU International 124, no. 3 (2019): 361–62. http://dx.doi.org/10.1111/bju.14877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Furuya, Hideki, and Charles J. Rosser. "Abstract P032: A novel multiplex immunoassay for the early detection of bladder cancer." Cancer Prevention Research 16, no. 1_Supplement (2023): P032. http://dx.doi.org/10.1158/1940-6215.precprev22-p032.

Full text
Abstract:
Abstract Background: We have identified a bladder cancer-associated signature which has been confirmed in several large cohorts, specifically noting its ability to identify smaller tumors (~1cm), which had an elevation at the time of diagnosis in one or more of the 10 biomarkers but not to the same extent as we see in the studies with primary de novo tumors (~3 cm). Thus, we have reported, as the tumor grows, as the grade increases and as the stage increases, there is a corresponding increase in the absolute levels of one or more of the biomarkers that comprise the bladder cancer-associated si
APA, Harvard, Vancouver, ISO, and other styles
25

Heer, Rakesh, Rebecca Lewis, Anne Duncan, et al. "Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT." Health Technology Assessment 26, no. 40 (2022): 1–144. http://dx.doi.org/10.3310/plpu1526.

Full text
Abstract:
Background Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule required after initial treatment has associated costs for patients and the NHS. In photodynamic diagnosis, before transurethral resection of bladder tumour, a photosensitiser that is preferentially absorbed by tumour cells is instilled intravesically. Transurethral resection of bladder tumour is then conducted under blue light, causing the photosensitiser to fluoresce. Photodynamic
APA, Harvard, Vancouver, ISO, and other styles
26

Zhang, Zhen, Florence Le Calvez-Kelm, Makito Miyake, et al. "Abstract A072: Oncuria®-Monitor, a non-invasive test for the detection of recurrent bladder cancer: Cross sectional performance evaluation from a multicenter study." Clinical Cancer Research 30, no. 21_Supplement (2024): A072. http://dx.doi.org/10.1158/1557-3265.liqbiop24-a072.

Full text
Abstract:
Abstract Up to 70% of patients with non-muscle invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the US. The purpose of this study was to test the performance of Oncuria®-Monitor, a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer. This cross-sectional, multicenter study included a total of 283 subjects with a history of bladder cancer. Voided urine specimens were collected prior to any procedures for multiplex analysis. The diagnostic performance of the biomarker panel was assessed usi
APA, Harvard, Vancouver, ISO, and other styles
27

Lepara, Zahid, Orhan Lepara, Almir Fajkić, Damir Rebić, Jasmin Alić, and Hajrudin Spahović. "Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer." Romanian Journal of Internal Medicine 58, no. 3 (2020): 146–52. http://dx.doi.org/10.2478/rjim-2020-0008.

Full text
Abstract:
AbstractIntroduction. Bladder cancer is the most common malignancy involving the urinary system. Recent research tends to emphasize the role of oxidative stress products in the carcinogenesis of bladder cancer. The level of oxidative stress can be measured by assessing the MDA levels. This study aimed to evaluate serum MDA levels in patients with bladder cancer, as well as to determine its potential role as a biomarker in the diagnosis of the disease and progression risk considerations.Methods. The study was designed as a cross-sectional study and included 90 patients, divided into three group
APA, Harvard, Vancouver, ISO, and other styles
28

Zhang, Hongshuo, Yue Fan, Lingling Xia, et al. "The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer." Tumor Biology 39, no. 3 (2017): 101042831769118. http://dx.doi.org/10.1177/1010428317691183.

Full text
Abstract:
Bladder cancer is the most common cancer of the urinary tract and can be avoided through proper surveillance and monitoring. Several genetic factors are known to contribute to the progression of bladder cancer, many of which produce molecules that serve as cancer biomarkers. Blood, urine, and tissue are commonly analyzed for the presence of biomarkers, which can be derived from either the nucleus or the mitochondria. Recent advances in proteomics have facilitated the high-throughput profiling of data generated from bladder cancer–related proteins or peptides in parallel with high sensitivity a
APA, Harvard, Vancouver, ISO, and other styles
29

Wang, Zhi-Yong, Hong-Yang Li, Hao Wang, Qiang Chi, Ying Liu, and Xiu-Ming Li. "Bladder Cancer–Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection." Disease Markers 2018 (September 10, 2018): 1–6. http://dx.doi.org/10.1155/2018/5609395.

Full text
Abstract:
Aims. Bladder cancer–specific nuclear matrix protein-4 (BLCA-4) is a protein expressed mainly in bladder cancer tissues. Therefore, the aim of this study was to investigate its assisting diagnostic potential in non-muscle-invasive bladder cancer (NMIBC). Methods. Twenty patients with NMIBC, 20 with benign prostatic hyperplasia (BPH), and 20 normal controls were included in this study. Blood and urine samples were collected from all patients. Moreover, cancer foci and adjacent tissue samples were collected from NMIBC patients, and normal bladder tissue samples were collected from patients with
APA, Harvard, Vancouver, ISO, and other styles
30

Christensen, Emil, Karin Birkenkamp-Demtröder, Himanshu Sethi, et al. "Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma." Journal of Clinical Oncology 37, no. 18 (2019): 1547–57. http://dx.doi.org/10.1200/jco.18.02052.

Full text
Abstract:
PURPOSE Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. PATIENTS AND METHODS We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep se
APA, Harvard, Vancouver, ISO, and other styles
31

Lodewijk, Iris, Marta Dueñas, Carolina Rubio, et al. "Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring." International Journal of Molecular Sciences 19, no. 9 (2018): 2514. http://dx.doi.org/10.3390/ijms19092514.

Full text
Abstract:
Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. Liquid biopsy represents a new non-invasive approach th
APA, Harvard, Vancouver, ISO, and other styles
32

Hu, Xinfeng, Yufan Xue, and Guodong Zhu. "Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma." Diagnostics 13, no. 5 (2023): 1004. http://dx.doi.org/10.3390/diagnostics13051004.

Full text
Abstract:
Upper tract urothelial carcinoma (UTUC) is a relatively rare, but highly malignant, disease with an estimated annual incidence of 2 cases per 100,000 people. The main surgical treatment modalities for UTUC are radical nephroureterectomy (RNU) with bladder cuff resection. After surgery, intravesical recurrence (IVR) can occur in up to 47% of patients, and 75% of them present with non-muscle invasive bladder cancer (NMIBC). However, there are few studies focused on the diagnosis and treatment of postoperatively recurrent bladder cancer for patients with previous UTUC history (UTUC-BC), and many
APA, Harvard, Vancouver, ISO, and other styles
33

Reynolds, Thomas, Gregory Riddick, Gregory Meyers, et al. "Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques." International Journal of Molecular Sciences 25, no. 1 (2023): 472. http://dx.doi.org/10.3390/ijms25010472.

Full text
Abstract:
Several studies have shown that microsatellite changes can be profiled in urine for the detection of bladder cancer. The use of microsatellite analysis (MSA) for bladder cancer detection requires a comprehensive analysis of as many as 15 to 20 markers, based on the amplification and interpretations of many individual MSA markers, and it can be technically challenging. Here, to develop fast, more efficient, standardized, and less costly MSA for the detection of bladder cancer, we developed three multiplex-polymerase-chain-reaction-(PCR)-based MSA assays, all of which were analyzed via a genetic
APA, Harvard, Vancouver, ISO, and other styles
34

Wu, Peng, Ziyi Cao, and Song Wu. "New Progress of Epigenetic Biomarkers in Urological Cancer." Disease Markers 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/9864047.

Full text
Abstract:
Urological cancers consist of bladder, kidney, prostate, and testis cancers and they are generally silenced at their early stage, which leads to the loss of the best opportunity for early diagnosis and treatment. Desired biomarkers are scarce for urological cancers and current biomarkers are lack of specificity and sensitivity. Epigenetic alterations are characteristic of nearly all kinds of human malignances including DNA methylation, histone modification, and miRNA regulation. Besides, the detection of these epigenetic conditions is easily accessible especially for urine, best target for mon
APA, Harvard, Vancouver, ISO, and other styles
35

Burchardt, Martin, Tatjana Burchardt, Ahmad Shabsigh, Alexandre De La Taille, Mitchell C. Benson, and Ihor Sawczuk. "Current Concepts in Biomarker Technology for Bladder Cancers." Clinical Chemistry 46, no. 5 (2000): 595–605. http://dx.doi.org/10.1093/clinchem/46.5.595.

Full text
Abstract:
Abstract Background: Transitional cell carcinoma of the bladder (TCC) is the second most common malignancy of the urinary tract. More than 70% of treated tumors recur, and 30% of recurrent tumors progress. Currently, pathologic staging and grading are valuable prognostic factors for detecting and monitoring TCC. Urinalysis, cystoscopy, and cytology are either invasive or lack sensitivity and specificity. The availability of a noninvasive, reliable, and simple test would greatly improve the detection and monitoring of patients with TCC. Several biomarkers for bladder cancer have been proposed,
APA, Harvard, Vancouver, ISO, and other styles
36

Ke, Chunjin, Zhiquan Hu, and Chunguang Yang. "UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives." Cancers 14, no. 21 (2022): 5423. http://dx.doi.org/10.3390/cancers14215423.

Full text
Abstract:
UroVysionTM is a fluorescence in situ hybridization assay that was developed for the detection of bladder cancer (UC accounted for 90%) in urine specimens. It consists of fluorescently labeled DNA probes to the pericentromeric regions of chromosomes 3, 7, 17 and to the 9p21 band location of the P16 tumor suppressor gene, which was approved by the Food and Drug Administration (FDA) in 2001 and 2005, respectively, for urine detection in patients with suspected bladder cancer and postoperative recurrence monitoring. Furthermore, recent studies also demonstrated that U-FISH was useful for assessin
APA, Harvard, Vancouver, ISO, and other styles
37

Kim, Youngkyu, Woo June Choi, Jungmin Oh, and Jun Ki Kim. "Compact Smartphone-Based Laser Speckle Contrast Imaging Endoscope Device for Point-of-Care Blood Flow Monitoring." Biosensors 12, no. 6 (2022): 398. http://dx.doi.org/10.3390/bios12060398.

Full text
Abstract:
Laser speckle contrast imaging (LSCI) is a powerful visualization tool for quantifying blood flow in tissues, providing simplicity of configuration, ease of use, and intuitive results. With recent advancements, smartphone and camera technologies are suitable for the development of smartphone-based LSCI applications for point-of-care (POC) diagnosis. A smartphone-based portable LSCI endoscope system was validated for POC diagnosis of vascular disorders. The endoscope consisted of compact LED and laser illumination, imaging optics, and a flexible fiberscope assembled in a 3D-printed hand-held ca
APA, Harvard, Vancouver, ISO, and other styles
38

Tanariyakul, Manasawee, Sakditad Saowapa, Natchaya Polpichai, et al. "Kidney outcomes in patients with bladder cancer: Insights from real-world data—A National Inpatient Sample (NIS) study, 2020." Journal of Clinical Oncology 42, no. 16_suppl (2024): e16622-e16622. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e16622.

Full text
Abstract:
e16622 Background: Bladder cancer constitutes a notable etiological factor in kidney disease, precipitating acute kidney injuries (AKI) through mechanisms such as post-renal obstruction, with the potential for progression to chronic kidney disease (CKD) over time. The objective of this study is to systematically evaluate the correlation between bladder cancer and the manifestation of acute or chronic kidney disease across various stages, with a focus on hospitalized patients undergoing treatment for bladder cancer. Methods: The 2020 United States National Inpatient Sample (NIS) database was su
APA, Harvard, Vancouver, ISO, and other styles
39

Hudson, MʼLiss A. "Prognostic factors and new methods for diagnosis and monitoring of patients with superficial bladder cancer." Current Opinion in Urology 3, no. 5 (1993): 399–404. http://dx.doi.org/10.1097/00042307-199310000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Abe, Masakazu, Hayato Hiraki, Takashi Tsuyukubo, et al. "Abstract 3326: The clinical validity of urinary pellet DNA monitoring of recurrent bladder cancer." Cancer Research 83, no. 7_Supplement (2023): 3326. http://dx.doi.org/10.1158/1538-7445.am2023-3326.

Full text
Abstract:
Abstract Introduction: Approximately half of high-risk non-muscle-invasive bladder cancers (NMIBCs) recur after transurethral resection of the bladder tumor (TURBT), whereas conventional urological testing for bladder cancer (BC) patients has been considered invasive and with low sensitivity. Our previous reports have shown that circulating tumor DNA (ctDNA) monitored by digital PCR (dPCR) can predict relapse and evaluate treatment efficacy in digestive tract cancers. In BC patients, tumor-derived genetic mutations detected in urinary DNA are expected to be a diagnostic biomarker. This study e
APA, Harvard, Vancouver, ISO, and other styles
41

Sturgeon, Catharine M., Michael J. Duffy, Barry R. Hofmann, et al. "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers." Clinical Chemistry 56, no. 6 (2010): e1-e48. http://dx.doi.org/10.1373/clinchem.2009.133124.

Full text
Abstract:
Abstract Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic
APA, Harvard, Vancouver, ISO, and other styles
42

Glosser, Logan D., Brandon S. Zakeri, Conner V. Lombardi, and Obi O. Ekwenna. "Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient." Case Reports in Transplantation 2022 (May 29, 2022): 1–4. http://dx.doi.org/10.1155/2022/5373414.

Full text
Abstract:
Introduction. Solid organ transplant increases the risk for muscle-invasive bladder cancer (MIBC). Although a common tumor, urothelial cell carcinoma (UCC) of the bladder in patients with kidney-pancreas transplants is scarcely reported. Case Presentation. A 65-year-old male with history of type 1 diabetes and a 14-year status post deceased donor pancreas-kidney transplant presented with 3 weeks of gross hematuria. CT scan showed multiple bladder masses. Transurethral resection of bladder tumor (TURBT) showed papillary UCC. 5 months later, the patient reported new-onset gross hematuria. TURBT
APA, Harvard, Vancouver, ISO, and other styles
43

Rossi, Raffaella, Miriam Lichtner, Francesco Iori, et al. "Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy." Archivio Italiano di Urologia e Andrologia 85, no. 4 (2013): 157. http://dx.doi.org/10.4081/aiua.2013.4.157.

Full text
Abstract:
Objectives: Immunotherapy with BCG (Bacille Calmette-Guérin) after transurethral resection of the bladder tumor represents a highly effective primary treatment for intermediate and high-risk superficial bladder cancer. The effectiveness of this therapy has been documented, but its mechanism of action is not clear yet. In the present study, we investigated the changes of dendritic cells (DC) numbers in peripheral blood and urine of patients with superficial bladder cancer undergoing BCG intravescical therapy Material and method: We have enumerated plasmacytoid and myeloid DCs in the peripheral
APA, Harvard, Vancouver, ISO, and other styles
44

T.V., Ishchuk, Glavachek D.O., Savchuk O.M., et al. "Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients." Biomedical Research and Therapy 5, no. 1 (2018): 1931–40. http://dx.doi.org/10.15419/bmrat.v5i1.407.

Full text
Abstract:
Background: Urinary bladder cancer (UBC) is the ninth most frequently diagnosed cancer worldwide. Early diagnosis and treatment can improve survival of patients. In order to improve the diagnostic accuracy of non-invasive urinary bladder cancer, a large number of tumor markers have been identified and strictly assessed. Some of the best candidates as predictive markers in oncologic diseases belong to the family of matrix metalloproteinases (MMPs). The main focus of investigation in this study was on MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and tissue inhibitor of metalloproteinase 1 (TIMP-1) as plasm
APA, Harvard, Vancouver, ISO, and other styles
45

Carrasco, Raquel, Mercedes Ingelmo-Torres, Ascensión Gómez, et al. "Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer." International Journal of Molecular Sciences 23, no. 19 (2022): 11732. http://dx.doi.org/10.3390/ijms231911732.

Full text
Abstract:
Cell-free DNA (cfDNA) has recently emerged as a real-time biomarker for diagnosis, monitoring and prediction of therapy response in tumoral disease. Here, we evaluated cfDNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer (MIBC) patients at different follow-up time points. Blood samples from 37 MIBC patients who underwent radical cystectomy (RC) were collected at cystectomy and 1, 4, 12 and 24 months later. Plasma cfDNA amount and fragmentation patterns were determined. Four mutations were analyzed in cfDNA to detect circulating tumor DNA (ctDNA) during patient follow-u
APA, Harvard, Vancouver, ISO, and other styles
46

Zaitsava, L. P., D. M. Los, V. N. Beliakovski, V. V. Pohozhay, and E. A. Nadyrov. "Liquid technology in the cytological diagnosis of bladder pathology." Health and Ecology Issues 18, no. 4 (2021): 61–68. http://dx.doi.org/10.51523/2708-6011.2021-18-4-8.

Full text
Abstract:
Objective. To study the effectiveness of liquid cytological diagnosis of bladder cancer and its local relapses using the Cellprep Plus technology as an example.Materials and methods. We analyzed outpatient records of patients with urothelial pathology (n = 806) who underwent a urine cytology exam by the methods of liquid (n = 383) and conventional (n = 423) cytology.Results. The diagnostic sensitivity and specificity of the cytological examination method for diagnosing urothelial carcinoma using the method of liquid cytology have been found to be 93.4 % and 95.4 % respectively, which significa
APA, Harvard, Vancouver, ISO, and other styles
47

Liu, H., T. Lin, W. He, et al. "Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment." European Urology Supplements 16, no. 3 (2017): e200. http://dx.doi.org/10.1016/s1569-9056(17)30188-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Miyake, Makito, Steve Goodison, Myron Chang, Yunfeng Dai, Virginia Urquidi, and Charles Joel Rosser. "A multi-analyte assay for the noninvasive detection of bladder cancer." Journal of Clinical Oncology 31, no. 6_suppl (2013): 306. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.306.

Full text
Abstract:
306 Background: Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. Methods: We performed a case-controlled validation study in which voided urines from 550 patients (220 tumor bearing subjects) were analyzed. The urinary concentrations of
APA, Harvard, Vancouver, ISO, and other styles
49

Ke, Hongying, Dandan Qiu, and Zhicheng Cong. "Prognosis Analysis and Perioperative Research of Elderly Patients with Non-Muscle-Invasive Bladder Cancer under Computed Tomography Image of Three-Dimensional Reconstruction Algorithm." Contrast Media & Molecular Imaging 2022 (June 6, 2022): 1–9. http://dx.doi.org/10.1155/2022/6168528.

Full text
Abstract:
To analyze the application value of computed tomography (CT) based on a three-dimensional reconstruction algorithm in perioperative nursing research and prognosis analysis of non-muscle-invasive bladder cancer (NMIBC), a retrospective study was performed on 124 patients with NMIBC who underwent surgical treatment in the hospital. All patients underwent CT examination based on the three-dimensional reconstruction algorithm before surgery, and transurethral resection of the bladder tumor was performed. The patients receiving conventional care were classified as the control group, and those recei
APA, Harvard, Vancouver, ISO, and other styles
50

Thomson, Alice, Aoife McVey, Brennan Timm, and Damien Bolton. "Urogenital Malignancy and Cannabis Use: A Narrative Review." Société Internationale d’Urologie Journal 4, no. 1 (2023): 51–64. http://dx.doi.org/10.48083/ndoj8638.

Full text
Abstract:
Background Cannabis is the most commonly used illicit drug worldwide. An increasing number of jurisdictions are legalising cannabis for both medicinal and recreational use. The changing cannabis market has resulted in both an increase in the number of people consuming these compounds, and an increase in the frequency and quantity of cannabis being used. Endogenous and exogenous cannabinoids act on receptors across the entire body including the genitourinary system; however, there is a paucity of understanding of how cannabinoids affect genitourinary malignancy. Objective To present a narrative
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography